Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
List view / Grid view
Filter the results
Ten medicines have been recommended for marketing authorisation and 10 extensions of indication have been suggested by the EMA.
Nestlé Health Science will acquire Aimmune Therapeutics for a total value of $2.6 billion, extending the former's food allergy portfolio.
Palforzia, a peanut allergen powder, has been approved for the reduction of allergic reactions in children aged four to 17. It is not an emergency treatment but instead designed to build tolerance.